New insights into predictors of cardiac implantable electronic device infection by Sadeghi, H. et al.
128      https://doi.org/10.14503/THIJ-17-6300
© 2018 by the Texas Heart ® 
Institute, Houston
Texas Heart Institute Journal • June 2018, Vol. 45, No. 3
New Insights into 
Predictors of Cardiac 
Implantable Electronic 
Device Infection
Infection is an important complication of cardiac implantable electronic device procedures. 
To further study the factors associated with infection, we retrospectively reviewed the 
records of 3,205 consecutive patients who had undergone de novo or revision cardiac 
electronic device implantation at our institution from March 2011 through March 2015. We 
recorded all infections and specified whether they were related to the characteristics of the 
patient, device, or procedure. To identify predictors of infection, we performed multivariate 
analysis.
Device infections were identified in 85 patients (2.7%), at a mean follow-up time of 
27 ± 11 months. The main predictors of device infection were use of an implantable car-
dioverter-defibrillator or a cardiac resynchronization therapy defibrillator device (odds ratio 
[OR]=16; 95% CI, 4.14–61.85; P=0.0001), stage 3 chronic kidney disease (OR=9.41; 95% CI, 
1.77–50.04; P=0.009), a revision procedure (OR=8.8; 95% CI, 3.37–23.2; P=0.0001), 
or postoperative hematoma (OR=6.9; 95% CI, 1.58–30.2; P=0.01). We also identified 2 
novel predictors of infection: a low body mass index of <20 kg/m2 (OR=1.03; 95% CI, 
1.01–1.06; P=0.005), and use of povidone-iodine rather than chlorhexidine-alcohol for topi-
cal antisepsis (OR=4.4; 95% CI, 2.01–9.4; P=0.03).
We conclude that comorbidities, device characteristics, procedure types, and postop-
erative noninfective complications all increase the risk of device infection after a cardiac 
implantable electronic device procedure. (Tex Heart Inst J 2018;45(3):128-35)
D uring the past 2 decades, the use of cardiac implantable electronic devices (CIEDs) has substantially increased; these include permanent pacemakers (PMs), implantable cardioverter-defibrillators (ICDs), and cardiac resyn-
chronization therapy (CRT) devices.1 From 1993 to 2008, a 96% increase in CIED 
implantation was reported in the United States, and this was accompanied by a 210% 
increase in the annual incidence of device-related infections during the same period.2 
These infections are associated with substantial morbidity and mortality rates and 
financial cost.3-6 In one European study, the additional healthcare costs for a patient 
with a CIED infection was more than 7,000 (comparable to $15,000 in the U.S.).7
 Several studies on predictors of CIED infections have been limited by small sample 
sizes, the examination of few variables, and conf licting results.8-13 To determine the 
predictors of device-related infections, we studied a relatively large population of pa-
tients who had undergone CIED implantation.
Patients and Methods
We retrospectively reviewed all recorded cases of CIED infection at our institution 
from March 2011 through March 2015. All cases were identified by using our hos-
pital’s computerized database and our electrophysiology laboratory index. An insti-
tutional review committee approved the study protocol, and the patients had given 
informed consent.
 Antibiotic Prophylaxis. We followed American Heart Association recommenda-
tions for preoperative antibiotic prophylaxis (1–2 g of cefazolin given intravenously 
within 1 hr before incision or, in case of cephalosporin allergy, 1 g of vancomycin 
given intravenously within 2 hr before incision).14 Whether patients received antibiot-
ics postoperatively was at the treating physician’s discretion. The protocol included 
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intravenous cefazolin or vancomycin, administered for 
one day after the procedure, and then oral ciprof loxa-
cin (250–500 mg twice/d for 5–7 d).
 Risk Factors. Risk factors for CIED infection were 
divided into 3 categories: 1) patient-related, including 
age, sex, body mass index (BMI); the lack of antibi-
otic prophylaxis, antiplatelet or anticoagulant use; and 
the presence of diabetes mellitus, renal failure, or heart 
failure; 2) device-related, including the use of a defi-
brillator device and implantation of ≥2 leads; and 3) 
procedure-related, including procedure duration, the 
use of a topical antiseptic for skin preparation, the use 
of a temporary pacemaker before CIED implantation, 
the presence of a postoperative hematoma, and the need 
for early reintervention or revision.
 Device Infection. Device infection can present as a 
suture line infection or pocket infection, or as infec-
tive endocarditis. A suture line infection was defined as 
localized inf lammation at the pocket incision, without 
evidence of pocket involvement.5 These infections are 
benign and do not necessitate device removal, so we in-
cluded only pocket infection and infective endocarditis 
in our final analysis.
 Pocket infection usually presents with redness, swell-
ing, warmth, f luctuation, erosion, or purulent dis-
charge.5 In contrast, infective endocarditis presents with 
fever, chills, malaise, and pulmonary symptoms, and it 
is diagnosed according to the modified Duke criteria 
(that is, the presence of an oscillating intracardiac mass 
on a valve or supporting structure, in the path of re-
gurgitant jets, or on implanted material in the absence 
of an alternative anatomic explanation).15 Infection was 
confirmed by positive cultures from a pocket swab or 
tissue sample obtained at the time of device removal, 
from a lead tip, or from blood.5 
 Operative Terms. The initial CIED implantation was 
defined as a de novo procedure. Generator replacement, 
lead revision, and system upgrades were considered to be 
revision procedures. Significant hematoma was defined 
as hematoma needing surgical evacuation, resulting in 
prolonged hospitalization for at least one day, or neces-
sitating interruption of anticoagulation therapy.16
 Evaluation of Kidney Function. We used the Cock-
croft–Gault equation17 to calculate the glomerular fil-
tration rate (GFR), as follows: 
Stage 3 chronic kidney disease (CKD) (GFR, <60 mL/
min/1.73 m2) has been associated with a significant in-
crease in device infection. Therefore, we used this cut-
off to evaluate the role of renal insufficiency on device 
infection.
Statistical Analysis
Statistical analysis was performed with SPSS version 
21.0 (SPSS, an IBM company). Continuous variables 
were presented as mean ± SD, and categorical variables 
were reported as frequencies with percentages. Compar-
isons between patients with and without infection were 
performed by using the Student t test for continuous 
variables and the Pearson χ2 or Fisher exact test for cat-
egorical variables. Risk factors for CIED infection were 
identified by binary logistic regression, using a stepwise 
approach. A 2-sided P value ≤0.05 was considered sta-
tistically significant.
Results
We enrolled 3,205 consecutive patients who underwent 
a CIED procedure (Table I). Their mean age was 62 ± 
16 years (range, 16–92 yr), and 1,997 (62%) were male. 
Of the CIEDs implanted, 843 were PMs, and 2,362 
were ICDs. Most (76%) of the devices had 2 or more 
leads. Of the total patients, 2,208 (69%) underwent a 
de novo procedure, and 997 (31%) underwent revision. 
The procedures were performed by 4 attending physi-
cians and 6 fellows-in-training.
 During a mean follow-up time of 27 ± 11 months, 
85 patients (3%) met the criteria for CIED infection 
TABLE I. Baseline Characteristics of the Study Population 
(N=3,205)
          Variable Value
   Male 1,997 (62)
   Diabetes mellitus 651 (20)
   Stage 3 CKD 36 (1)
   Device  
      Permanent PM 843 (26) 
      ICD 2,362 (74) 
      Multiple-lead device 2,434 (76) 
      Temporary PM 624 (19)
   Procedure  
      De novo 2,208 (69) 
      Revision 997 (31) 
         Generator replacement 738 (23) 
         Lead revision 160 (5) 
         Upgrade 99 (3)
   Antithrombotic therapy  
      Anticoagulant 318 (10) 
      Antiplatelet 1,543 (48) 
      Combined 387 (12)
   Antibiotic therapy  
      Preoperative 3,205 (100) 
      Postoperative 1,663 (52)
 
CKD = chronic kidney disease; ICD = implantable cardioverter-
defibrillator; PM = pacemaker 
 
Data are presented as number and percentage.
GFR (mL/min/1.73 m2) =
[140 – age (yr)] × weight (kg)
72 × serum creatinine (mg/dL)
(× 0.85 if female).
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(infection rate, 2.7%); infections were microbiologically 
confirmed in 96% of these patients. Coagulase-negative 
staphylococci and Staphylococcus aureus were responsible 
for 80% of the infections; streptococci and gram-nega-
tive bacilli caused the remaining 20%. Most infections 
(n=61, 72%) occurred within the first year after device 
implantation: there were 11 (13%) in the first month, 
33 (39%) in months 2 through 6, and 17 (20%) in 
months 7 through 12. The mean time from device 
implantation to infection was similar for de novo and 
revision procedures (9.4 ± 12 vs 11 ± 9 mo; P=0.56). 
The onset of infection was earlier in patients with ICDs 
than in those with pacemakers, but this did not reach 
statistical significance (6 ± 8 vs 9 ± 8 mo; P=0.19).
 Of the 85 patients with infection, 14 (16.5%) had a 
PM, and 71 (83.5%) had an ICD. Eight (9.5%) had 
suture line infections, 74 (87%) had pocket infections, 
and 3 (3.5%) had endocarditis. In comparison of infec-
tion type by device type, suture line infections occurred 
in 3 (27%) patients with PMs and in 5 (7%) with 
ICDs, and pocket infections occurred in 11 (73%) with 
PMs and in 63 (89%) with ICDs. The 3 (4%) patients 
with endocarditis had ICDs: one had a dual chamber 
ICD, and the other 2 had a cardiac resynchronization 
therapy defibrillator (CRT-D). Infection occurred after 
a de novo procedure in 42 (49%) patients, and after a 
revision procedure in 43 (51%) patients.
 Patient-Related Factors. Table II compares the baseline 
characteristics of patients with and without CIED in-
fection. The patients in the group with infection were 
more likely to have diabetes mellitus (32% vs 20%; 
P=0.008), stage 3 CKD (9.4% vs 0.9%; P=0.0001), 
and a low BMI (25 vs 27 kg/m2; P=0.04). Of note, 
more patients with CRT devices had diabetes than 
did those with other types of CIEDs (34% vs 15%; 
P=0.0001).
 All patients received preoperative antibiotic pro-
phylaxis. In both groups, fewer patients received an-
tibiotics postoperatively, but the lack of postoperative 
therapy was more prevalent in the group with infection 
(P=0.0001). Previous therapy with antiplatelet drugs, 
anticoagulant drugs, or both was not associated with 
an increased risk of infection (all P >0.05).
 Device-Related Factors. The infection rate was higher 
in patients with ICDs than in those with PMs (3% vs 
1.7%; P=0.04), as well as in patients with ≥2 leads than 
in those with one lead (3% vs 1.3%; P=0.004) (Table 
III).
 Infection was most likely to occur in patients who 
had a CRT-D device (3.5%). The infection rate was 
0.6% in patients with single chamber PMs and 2% in 
those with ICDs. In patients with dual chamber de-
vices, the infection rate was 2.4% for PMs and 2.8% 
for ICDs. No infection was detected in patients with 
CRT pacemaker (CRT-P) devices (Fig. 1).
 Procedure-Related Factors. Temporary PM use be-
fore permanent device implantation was associated 
with a higher rate of device infection (4.5% vs 2.2%; 
P=0.001). The type of antiseptic solution used for skin 
preparation also had a clear effect on the device infec-
tion rate; 5.8% of patients receiving topical antisepsis 
with povidone-iodine had device infection, compared 
TABLE II. Patient Characteristics Compared in Terms of 
Device Infection
 Device No Device 
 Infection Infection 
          Variable (n=85) (n=3,120) P Value
Age (yr) 61 ± 17 62 ± 16 0.63
Male 60 (71) 1,937 (62) 0.11
LV function 0.30 ± 0.14 0.29 ± 0.14 0.42
Body mass index (kg/m2) 25 ± 5 27 ± 5 0.04
Diabetes mellitus 27 (32) 624 (20) 0.008
Stage 3 CKD 8 (9) 28 (0.9) 0.0001
Antithrombotic therapy    
   Anticoagulant 6 (7) 312 (10) 0.4 
   Antiplatelet 43 (50) 1,500 (48) 0.5 
   Combined 10 (12) 377 (12) 0.75
Antibiotic therapy  
   Preoperative 85 (100) 3,120 (100) 1 
   Postoperative 25 (29) 1,638 (53) 0.0001
 
CKD = chronic kidney disease; LV = left ventricular 
 
Data are presented as mean ± SD or as number and percentage. 
P ≤0.05 was considered statistically significant.
TABLE III. Device and Procedural Characteristics 
Compared in Terms of Device Infection
 Device No Device 
 Infection Infection 
          Variable (n=85) (n=3,120) P Value
ICD or CRT-D device 71 (84) 2,291 (73) 0.037
Multiple leads 74 (87) 2,285 (73) 0.004
Procedural time (hr) 1.9 ± 0.6 1.6 ± 0.7 0.001
Topical skin antisepsis — — 0.0001
   Povidone-iodine 49 (58) 793 (25) —
   Chlorhexidine-alcohol 36 (42) 2,327 (75) —
Temporary PM 28 (33) 596 (19) 0.001
Procedure — — 0.0001
   De novo 42 (49) 2,166 (69) —
   Revision 43 (51) 954 (31) —
Postoperative hematoma 9 (11) 53 (1.7) 0.0001
 
CRT-D = cardiac resynchronization therapy defibrillator; ICD = 
implantable cardioverter-defibrillator; PM = pacemaker 
 
Data are presented as number and percentage or as mean ± SD. 
P ≤0.05 was considered statistically significant.
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to 1.5% of those receiving antisepsis with chlorhexi-
dine-alcohol (P=0.0001). The operator had no effect 
on the rate of infection (P=0.8).
 The mean procedural duration was longer in the 
group with infection than in the group without infec-
tion (1.9 ± 0.6 vs 1.6 ± 0.7 hr; P=0.001), and the risk 
of infection was higher after revision than after de novo 
procedures (4.3% vs 1.9%; P=0.0001). Of note, pa-
tients with CRT devices underwent signif icantly lon-
ger procedures than did those with non-CRT devices 
(mean, 2 ± 0.6 vs 1.65 ± 0.7 hr; P=0.001), and they 
underwent more revision procedures (61% vs 36%; 
P=0.001). The infection rate in patients with postop-
erative hematoma was also higher than in those without 
hematoma (14.5% vs 2.4%; P=0.0001) (Table III). All 
hematomas resolved without intervention.
Multivariate Analysis
All variables with P values <0.1 on univariate analysis 
were evaluated in a stepwise multivariate binary logistic 
regression model. A BMI <20 kg/m2 was associated with 
infection (sensitivity, 87%; specificity, 83%); therefore, 
we used 20 kg/m2 as the BMI cutoff in the regression 
analysis. A procedural time >2 hours (sensitivity, 90%; 
specif icity, 95%) was also a predictor of device infec-
tion. On f inal analysis, the following variables were 
found to be independent predictors of CIED infection 
(Table IV): low BMI (odds ratio [OR]=1.035; 95% 
CI, 1.01–1.06; P=0.005), diabetes mellitus (OR=2.29; 
95% CI, 1.04–5.09; P=0.04), stage 3 CKD (OR=9.41; 
95% CI, 1.77–50.04; P=0.009), temporary PM use 
before permanent device implantation (OR=5.7; 95% 
CI, 1.38–23.3; P=0.0001), postoperative hematoma 
(OR=6.9; 95% CI, 1.58–30.2; P=0.01), a revision 
procedure (OR=8.8; 95% CI, 3.37–23.2; P=0.0001), 
povidone-iodine rather than chlorhexidine-alcohol 
antisepsis (OR=4.4; 95% CI, 2.01–9.4; P=0.03), a 
procedural time >2 hr (OR=2.6; 95% CI, 1.5–4.8; 
P=0.0001), and implantation of an ICD or CRT-D 
(OR=16; 95% CI, 4.14–61.85; P=0.0001). Other fac-
Fig. 1  Chart shows device type and procedure category in patients with and without infection. 
 
CRT = cardiac resynchronization therapy; ICD = implantable cardioverter-defibrillator
Total population
N=3,205
No infection group
n=3,120
Pacemaker 
n=829
Single chamber
n=330
De novo=280
Revision=50
Dual chamber
n=479
De novo=339
Revision=140
CRT pacemaker
n=20
De novo=18
Revision=2
ICD 
n=2,291
Single chamber
n=430
De novo=278
Revision=152
Dual chamber
n=790
De novo=500
Revision=290
CRT defibrillator 
n=1,071
De novo=751
Revision=320
Infection group 
n=85
Pacemaker
n=14
Single chamber
n=2
Revision=2 
Dual chamber
n=12
De novo=6
Revision=6
CRT pacemaker 
n=0
ICD 
n=71
Single chamber 
n=9
De novo=5
Revision=4
Dual chamber
n=23
De novo=12
Revision=11
CRT defibrillator 
n=39
De novo=19
Revision=20
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tors significant in univariate analysis, including multi-
ple leads and postoperative antibiotic prophylaxis, were 
not independent predictors in the multivariate model.
Discussion
Several important f indings emerged from our study. 
First, our investigation clearly showed that low BMI 
increases the risk of device infection (to our knowl-
edge, no other studies have confirmed this). Second, 
skin preparation with chlorhexidine-alcohol was more 
protective than that with povidone-iodine. Third, ICD 
or CRT-D implantation was the strongest predictor 
of CIED infection; PM procedures resulted in fewer 
cases of device infection. Fourth, patients treated with 
a temporary PM before undergoing a permanent CIED 
procedure were more than 5 times as likely to develop 
a device infection than those who were not. Fifth, non-
infective postoperative complications, such as hema-
toma, and revision procedures were associated with an 
increased risk of device infection.
 In this large single-center experience with PM, ICD, 
and CRT procedures, the infection rate was 2.7% at 
2.25 years (annual incidence, 1.2%). The device infec-
tion rate was 1.7% in patients with PMs and 3% in 
those with ICDs, and patients with CRT-D devices had 
the highest infection rate (3.5% at 2.25 yr; annual in-
cidence, 1.55%). Single chamber PM procedures were 
complicated by infection in only 0.6% of patients dur-
ing the same follow-up time. No patients with CRT-P 
devices had infections. Only 3.5% of patients with 
CIED infections presented with infective endocarditis. 
The overall infection rate observed in our series is com-
parable to that reported in other studies.18-23 The low 
incidence of endocarditis in our series may be explained 
by the administration of postoperative antibiotics in 
29% of the patients. 
 Romeyer-Bouchard and colleagues18 reported an 
infection rate of 4.3% at 2.6 years (annual incidence, 
1.7%) for patients who had received CRT devices. Simi-
larly, a 1-year infection rate of 1.77% was reported in the 
Prospective Evaluation of Pacemaker Lead Endocardi-
tis (People) registry of patients with CRT devices.19 No 
CRT-P infections were reported in the Complication 
Rates associated with Pacemaker or Implantable Car-
dioverter-Defibrillator Generator REPLACEments and 
Upgrade Procedures (Replace) registry20; this finding, 
which was similar to ours, may be explained by the very 
small number of patients with CRT-P devices in both 
studies. Mounsey and colleagues21 reported an infection 
rate of 2.7% at a mean follow-up time of 19 months in 
patients with permanent PMs or ICDs, and Cengiz and 
associates22 reported a rate of 2.45% at a mean follow-
up time of 35 months. Mittal and colleagues23 reported 
an infection rate of 2.9% within the first 6 months in 
patients with ICD or CRT-D devices.
 Among the patient-related risk factors for CIED in-
fection, diabetes mellitus, renal failure, and low BMI 
were associated with a higher risk of infection. Although 
there are conf licting reports, a recent meta-analysis has 
identif ied diabetes as a risk factor for infection,24 and 
our investigation supports this finding; the risk of infec-
tion in diabetic patients was twice that in nondiabetic 
patients, which may be related to the immunosuppres-
sive effect of longstanding hyperglycemia. Therefore, 
blood glucose control should be an integral part of pa-
tient preparation programs, especially before elective 
CIED procedures. Before a procedure, a glyco sylated 
hemoglobin level of <7% is recommended, and the 
morning after the procedure, the target blood glucose 
level is <180 mg/dL.25
 In our study population, moderate-to-severe renal 
dysfunction (GFR, <60 mL/min/1.73 m2) significantly 
increased the risk of infection after a CIED procedure 
(P=0.009), and similar results have been documented 
in previous studies.8,26 The heightened risk of infection 
is related to uremia-induced immunodeficiency, bac-
teremia due to repeated intravenous access, associated 
comorbidities, and elevated risks of bleeding and pocket 
hematoma.
 A low BMI, which is associated with a thin subcuta-
neous fat layer, may predispose patients to skin erosion 
and secondary pocket infections. In addition, the higher 
incidence of post-CIED hematoma in patients with a 
low BMI may explain the association between low BMI 
and infection.27
 Among the device-related factors, implantation of an 
ICD or CRT-D was the strongest predictor of CIED 
infection (OR=16; 95% CI, 4.14-61.85; P=0.0001). 
The higher infection rate associated with ICDs, espe-
TABLE IV. Multivariate Analysis of Infection Predictors
          Variable Odds Ratio (95% CI) P Value
ICD or CRT-D device 16 (4.14–61.85) 0.0001
Stage 3 CKD 9.41 (1.77–50.04) 0.009
Revision procedure 8.8 (3.37–23.2) 0.0001
Postoperative hematoma 6.9 (1.58–30.2) 0.01
Temporary PM 5.7 (1.38–23.3) 0.0001
Povidone-iodine 4.4 (2.01–9.4) 0.03
Procedure >2 hr 2.6 (1.5–4.8) 0.0001
Diabetes mellitus 2.29 (1.04–5.09) 0.04
BMI <20 kg/m2 1.03 (1.01–1.06) 0.005
 
BMI = body mass index; CKD = chronic kidney disease; CRT-D 
= cardiac resynchronization therapy defibrillator; ICD = implant-
able cardioverter-defibrillator; PM = pacemaker 
 
P ≤0.05 was considered statistically significant.
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cially CRT-Ds, is most likely related to longer proce-
dural times, the presence of multiple leads, the higher 
incidence of early reintervention for left ventricular lead 
complications, and the higher incidence of associated 
comorbidities. A larger generator size may also predis-
pose the patient to skin necrosis and subsequent pocket 
infection. Nery and colleagues28 monitored 2,417 pa-
tients who underwent CIED procedures and identified 
CRT device and generator replacement as independent 
predictors of infection. Similarly, Margey and associ-
ates11 reported implantation of a biventricular device as 
an independent predictor of infection in a study of 3,105 
patients (OR=7.57; 95% CI, 2.4–23.7; P=0.0001), and 
Palmisano and colleagues’ retrospective analysis of 
2,671 patients29 showed that CRT device implantation 
was an independent predictor of infection (OR=28.54; 
95% CI, 3.49–233.07; P=0.002) during a median fol-
low-up time of 27 months.
 In our evaluation of procedure-related factors, the 
presence of a transvenous temporary PM at the time 
of permanent device implantation increased the risk 
of device infection by more than 5-fold. This f inding 
agrees with those in previous studies.30-32 Use of tempo-
rary PMs may increase the risk of bacteremia and of a 
secondary CIED infection. In addition, these devices 
are usually implanted in an urgent situation, which pre-
vents appropriate antibiotic administration. Therefore, 
a temporary PM should be implanted only when there 
are no viable alternatives, and it should be removed as 
soon as possible to reduce the risk of infection. 
 The current study also shows that preoperative skin 
cleansing with chlorhexidine-alcohol is more protec-
tive against CIED infection than is povidone-iodine. 
Previous investigators33,34 have reported this result in 
clean-contaminated surgeries—such as colorectal, bili-
ary, and gynecologic operations—and in intravascular 
catheter procedures. However, 2 other studies35,36 re-
vealed no advantages of one antibiotic over the other in 
preventing CIED infection. Our investigation is, to our 
knowledge, the first to show that topical antisepsis with 
povidone-iodine is an independent predictor of infec-
tion in patients undergoing CIED procedures. 
 Revision procedures, including generator replace-
ments, lead revisions, and system upgrades, were asso-
ciated with an 8.8-fold greater risk of infection. The risk 
was especially high in patients who needed early reinter-
vention for lead malfunctions or who underwent system 
upgrades. It has been suggested that this risk is related 
to bacterial contamination of the avascular capsule that 
forms around the generator, which may hinder the dif-
fusion of systemic antibiotics and inf lammatory cells 
to the device pocket site.37-39 This finding is particularly 
relevant in regard to generator or lead advisories and re-
call notices. Before a device is replaced, the benefits and 
risks of device and accessory replacement—including 
the risk of death due to device failure, the rate of device 
failure, and the risk of procedure-related death—should 
be carefully considered.40
 Our study, as did that of Romeyer-Bouchard and 
colleagues,18 showed that procedure duration is an in-
dependent predictor of infection, which is especially 
relevant in patients who are candidates for CRT device 
implantation. Improvements in left ventricular lead 
design, delivery systems, and over-the-wire technology 
may substantially shorten procedure time and decrease 
the likelihood of infection.
 Investigators have frequently correlated postopera-
tive hematoma with CIED infection.16 We confirmed 
this finding in our study: the risk of infection increased 
nearly 7-fold in patients who had a substantial hema-
toma. Similarly, in the Bruise control infection 
study (Bridge or Continue Coumadin for Device Sur-
gery Randomized Controlled Trial Extended Follow-
Up for Infection), Essebag and colleagues16 found that 
hematoma increased the risk of infection 7.7-fold by 
mechanisms including tissue necrosis due to compres-
sive effects of a blood clot in the suture line, breaches 
in wound healing, contamination caused by wound 
tension from a hematoma, and the presence of a fertile 
environment for microorganism colonization. Conse-
quently, to reduce the risk of hematoma in patients 
undergoing CIED procedures, bleeding sites should be 
meticulously cauterized to ensure adequate hemostasis; 
antiplatelet and anticoagulation therapy should be inter-
rupted before the procedure when feasible; and pressure 
dressings should be applied for the first 12 to 24 hours 
after the procedure.
Study Limitations
The limitations of our study are those of a retrospective 
analysis, including selection bias and missing data. To 
reduce selection bias, we used a standardized definition 
of device infection, a similar implantation strategy, and 
the same anticoagulation and antibiotic protocols. Our 
study was also limited because it included patients from 
a single center. However, the infection rate and pattern 
among our patients were like those seen in large patient 
registries, such as People and Replace. 
Conclusion
We identified several predictors of device infection in a 
relatively large series of patients who underwent CIED 
procedures and found that most infections are related to 
the device characteristics, the procedure type, and the 
postoperative noninfective complications. Taking ap-
propriate interventional measures for modifiable factors 
may dramatically reduce device-related infection; these 
measures include optimizing blood sugar level and renal 
function before a procedure, preoperative skin cleansing 
with chlorhexidine-alcohol, shortening the procedure 
time, avoiding unnecessary temporary PM implanta-
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tions, appropriately f ixating leads, and establishing 
blood hemostasis during the procedure.
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